Avenue Therapeutics’ AJ201: A Buy Rating for Innovative SBMA Treatment and Promising Clinical Progress

Maxim Group analyst Jason McCarthy maintained a Buy rating on Avenue Therapeutics (ATXI – Research Report) yesterday and set a price target of $0.75.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding the potential of Avenue Therapeutics’ drug candidate, AJ201, and its implications for the treatment of spinal bulbar muscular atrophy (SBMA). His optimism is partly rooted in AJ201’s unique three-fold mechanism of action, which not only targets the degradation of the abnormal androgen receptor protein that accumulates in SBMA patients but also stimulates Nrf1 and Nrf2 pathways that are essential for cellular protection against oxidative stress. The innovative nature of this treatment could position Avenue Therapeutics favorably in the high-value neuromuscular disorder market, as evidenced by the significant industry acquisition of Reata Pharmaceuticals following their drug approval for a similar condition.
Furthermore, McCarthy’s confidence is bolstered by the timely progression of AJ201’s Phase 1b/2a study, which met its enrollment target in January 2024 and is on schedule to deliver top-line data in the second quarter of 2024. The upcoming virtual KOL event promises to provide valuable expert insights ahead of this crucial data release, potentially affirming AJ201’s therapeutic benefit. Positive outcomes from these studies could lead to pivotal meetings with the FDA, paving the way for further development and eventual commercialization, which, in turn, could drive Avenue Therapeutics’ stock value significantly higher.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Avenue Therapeutics (ATXI) Company Description:

Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.